Table 2.
Breast cancer mortality according to AR status, stratified by ER status and according to combinations of AR and ER status. Crude and adjusted models are presented for the overall follow-up period, for 0–5 years and >5 years of follow-up
| Follow-up period and subgroup | HRs | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow-up | Crude | Model 1a | Model 2b | ||||||||
| Subgroups | Total (n) | Events (n) | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P |
| Overall | |||||||||||
| AR+ vs. AR− | |||||||||||
| All patients | 671 | 93 | 0.48 | 0.30–0.77 | 0.002 | 1.06 | 0.59–1.92 | 0.84 | 1.12 | 0.62–2.04 | 0.71 |
| ER+ | 543 | 65 | 0.64 | 0.33–1.26 | 0.20 | 0.95 | 0.47–1.92 | 0.89 | 1.02 | 0.51–2.04 | 0.97 |
| ER− | 76 | 19 | 0.70 | 0.28–1.75 | 0.45 | 1.44 | 0.46–4.54 | 0.53 | 1.16 | 0.34–4.00 | 0.81 |
| 0.91c | 0.58 c | 0.63 c | |||||||||
| ER missingd | 52 | 9 | 0.17 | 0.04–0.76 | 0.02 | –e | – | – | –e | – | – |
| AR and ER | |||||||||||
| ER+AR+ | 489 | 55 | Ref. | Ref. | Ref. | ||||||
| ER−AR− | 37 | 11 | 2.94 | 1.54–5.62 | 0.001 | 1.49 | 0.73–3.03 | 0.27 | 0.83 | 0.33–2.07 | 0.69 |
| ER+AR− | 54 | 10 | 1.57 | 0.80–3.08 | 0.19 | 1.05 | 0.53–2.11 | 0.88 | 0.98 | 0.49–1.96 | 0.95 |
| ER−AR+ | 39 | 8 | 2.01 | 0.95–4.22 | 0.07 | 1.96 | 0.91–4.20 | 0.08 | 1.14 | 0.47–2.77 | 0.78 |
| 0–5 years | |||||||||||
| AR+ vs. AR− | |||||||||||
| All patients | 671 | 43 | 0.37 | 0.19–0.71 | 0.003 | 1.33 | 0.56–3.15 | 0.52 | 1.22 | 0.51–2.92 | 0.66 |
| ER+ | 543 | 25 | 0.56 | 0.19–1.62 | 0.28 | 0.91 | 0.30–2.73 | 0.86 | 0.93 | 0.31–2.81 | 0.89 |
| ER− | 76 | 13 | 0.84 | 0.28–2.49 | 0.75 | 1.73 | 0.51–5.92 | 0.38 | 1.37 | 0.38–4.97 | 0.63 |
| 0.60c | 0.35c | 0.50c | |||||||||
| ER missing | 52 | 5 | 0.20 | 0.03–1.19 | 0.08 | –e | – | – | –e | – | – |
| AR and ER | |||||||||||
| ER+AR+ | 489 | 21 | Ref. | Ref. | Ref. | ||||||
| ER−AR− | 37 | 7 | 4.85 | 2.06–11.41 | 0.0003 | 1.86 | 0.74–4.67 | 0.18 | 1.36 | 0.38–4.82 | 0.63 |
| ER+AR− | 54 | 4 | 1.78 | 0.61–5.19 | 0.29 | 1.10 | 0.37–3.29 | 0.87 | 1.06 | 0.35–3.20 | 0.91 |
| ER−AR+ | 39 | 6 | 4.09 | 1.65–10.14 | 0.002 | 3.55 | 1.38–9.13 | 0.009 | 2.23 | 0.68–7.27 | 0.19 |
| >5 years | |||||||||||
| AR+ vs. AR− | |||||||||||
| All patients | 553 | 50 | 0.61 | 0.31–1.20 | 0.15 | 0.91 | 0.41–2.02 | 0.83 | 1.09 | 0.48–2.45 | 0.83 |
| ER+ | 451 | 40 | 0.70 | 0.29–1.68 | 0.43 | 0.98 | 0.40–2.41 | 0.96 | 1.08 | 0.44–2.66 | 0.87 |
| ER− | 56 | 6 | 0.46 | 0.08–2.57 | 0.38 | 0.12 | 0.001–12.36 | 0.37 | –e | – | – |
| 0.65c | –e | –e | |||||||||
| ER missing | 41 | 4 | 0.11 | 0.007–1.82 | 0.12 | –e | – | – | –e | – | – |
| AR and ER | |||||||||||
| ER+AR+ | 408 | 34 | Ref. | Ref. | – | ||||||
| ER−AR− | 29 | 4 | 1.75 | 0.62–4.92 | 0.29 | 1.17 | 0.37–3.68 | 0.78 | –e | – | – |
| ER+AR− | 43 | 6 | 1.43 | 0.60–3.42 | 0.42 | 1.02 | 0.42–2.52 | 0.96 | – | – | – |
| ER−AR+ | 27 | 2 | 0.78 | 0.19–3.27 | 0.74 | 0.83 | 0.20–3.53 | 0.80 | – | – | – |
AR androgen receptor, CI confidence interval, ER estrogen receptor alpha, HR hazard ratio
aAdjusted for age at diagnosis (continuous), tumor size >20 mm yes/no, ALNI ≥ 1 metastatic node yes/no, Grade III yes/no and ER status ± . Complete case analysis. 80 patients excluded in the analysis of all patients due to missing values for one or more of the variables in the model
bAdjusted as in model 1, but also for planned adjuvant treatments (chemotherapy yes/no, radiotherapy yes/no, endocrine treatment yes/no). Complete case analysis. 138 patients excluded in the analysis of all patients due to missing values for one or more of the variables in the model
c P value for interaction
dAR distribution among ER missing: 45 AR+ and 7 AR−
eToo few patients left for meaningful analyses